Our Firm is representing a number of men and boys who have filed Risperdal gynecomastia claims in this proceeding. We will be monitoring this matter very closely.
New York, New York (PRWEB) May 27, 2014
As Risperdal lawsuits (http://www.injurybeacon.com/risperdal/lawsuit/) continue to mount in a mass tort litigation underway in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP notes that the defense is seeking partial summary judgment in certain Risperdal gynecomastia cases on the grounds that they are time-barred. In a Motion filed on May 19, 2014, Johnson & Johnson and its Janssen Pharmaceuticals unit assert that plaintiffs were on notice of a potential connection between Risperdal and male breast growth by October 31, 2006. As such, the Motion contends that the statute of limitations for any alleged injury sustained prior to that date began to run no later than October 31, 2006. The Motion also claims that the statute of limitations governing cases where an alleged injury occurred after October 31, 2006 would have begun to run no later than the date of the injury. (Risperdal Litigation, case number 100300296)
“Our Firm is representing a number of men and boys who have filed Risperdal gynecomastia claims in this proceeding. We will be monitoring this matter very closely,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.
According to court documents, more than 500 Risperdal lawsuits are pending in the Pennsylvania litigation on behalf of individuals who were allegedly injured by the atypical antipsychotic medication. All of the Risperdal gynecomastia claims were filed on behalf of men and boys who allegedly experienced excessive growth of breast tissue while using the drug. Among other things, Johnson & Johnson and Janssen are accused of concealing side effects associated with the medication, including the link between Risperdal and gynecomastia. Plaintiffs further allege that the defendants improperly marketed Risperdal for off-label uses, including the treatment of children long before pediatric indications were approved in 2006.
Risperdal is an atypical antipsychotic medication that is approved to treat adult and adolescent schizophrenia, as well as bipolar disorder in adults and children ages 10-to-17. Risperdal is also approved to treat irritability in children (5-to-16 years of age) with autistic disorder. Risperdal lawsuits allege that the medication can cause the body to produce excessive amounts of prolactin, a hormone which is known to stimulate breast growth and milk production in women, as well as the development of excess breast tissue in male patients.
In November 2013, Johnson & Johnson and Janssen agreed to pay $2.2 billion to settle allegations brought against them by the U.S. Department of Justice over the marketing of Risperdal and other medications. Among other things, the government had charged the companies with improperly marketing Risperdal for use in children, and further alleged that they had concealed the link between Risperdal and gynecomastia, as well as other side effects. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Alleged victims of Risperdal and gynecomastia may be entitled to compensation for medical bills, lost wages, pain and suffering and more. Find out more about filing a Risperdal lawsuit by visiting Bernstein Liebhard LLP’s website. Free case reviews may also be obtained by calling the Firm directly at 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com